Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P W Collins

Showing results (71-80 of 151) with videos related to

Pageof 16
Sort By:
British Journal of Haematology|November 25, 2000
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)C R Hay, T P Baglin, P W Collins, et al.
British Journal of Haematology|May 1, 1995
Administration of rHuGM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapyM A Williams, S M Kelsey, P W Collins, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 15, 2017
The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors OrganisationC R M Hay, H Xiang, M Scott, et al.
Journal of Medicinal Chemistry|September 1, 1977
Synthesis and gastric antisecretory properties of 15-deoxy-16-hydroxyprostaglandin E analoguesP W Collins, E Z Dajani, D R Driskill, et al.
Thrombosis and Haemostasis|August 26, 2000
Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factorL Hilbert, P V Jenkins, C Gaucher, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 22, 2001
Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experienceP Chowdary, H Dasani, J A Jones, et al.
Journal of Medicinal Chemistry|June 1, 1983
Synthesis and gastric antisecretory properties of 4,5-unsaturated derivatives of 15-deoxy-16-hydroxy-16-methylprostaglandin E1P W Collins, E Z Dajani, R Pappo, et al.
International Journal of Obstetric Anesthesia|July 16, 2022
A description of the coagulopathy characteristics in amniotic fluid embolism: a case reportC Oliver, J Freyer, M Murdoch, et al.
British Journal of Haematology|October 16, 1999
Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?R M MacLean, G P Feeney, S J Bowley, et al.
Journal of Thrombosis and Haemostasis : JTH|March 27, 2009
Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohortP W Collins, M Mathias, J Hanley, et al.
Pageof 16

Showing results (71-80 of 151) with videos related to

Sort By:
Pageof 16
British Journal of Haematology|November 25, 2000
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)C R Hay, T P Baglin, P W Collins, et al.
British Journal of Haematology|May 1, 1995
Administration of rHuGM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapyM A Williams, S M Kelsey, P W Collins, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 15, 2017
The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors OrganisationC R M Hay, H Xiang, M Scott, et al.
Journal of Medicinal Chemistry|September 1, 1977
Synthesis and gastric antisecretory properties of 15-deoxy-16-hydroxyprostaglandin E analoguesP W Collins, E Z Dajani, D R Driskill, et al.
Thrombosis and Haemostasis|August 26, 2000
Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factorL Hilbert, P V Jenkins, C Gaucher, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 22, 2001
Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experienceP Chowdary, H Dasani, J A Jones, et al.
Journal of Medicinal Chemistry|June 1, 1983
Synthesis and gastric antisecretory properties of 4,5-unsaturated derivatives of 15-deoxy-16-hydroxy-16-methylprostaglandin E1P W Collins, E Z Dajani, R Pappo, et al.
International Journal of Obstetric Anesthesia|July 16, 2022
A description of the coagulopathy characteristics in amniotic fluid embolism: a case reportC Oliver, J Freyer, M Murdoch, et al.
British Journal of Haematology|October 16, 1999
Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?R M MacLean, G P Feeney, S J Bowley, et al.
Journal of Thrombosis and Haemostasis : JTH|March 27, 2009
Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohortP W Collins, M Mathias, J Hanley, et al.
Pageof 16